Document 0252
 DOCN  M95B0252
 TI    Neutralizing antibodies against highly cytopathic Zairian human
       immunodeficiency type-1 virus (HIV-1) NDK are present in sera outside
       Africa.
 DT    9511
 AU    Machado AA; Bakpabua M; Salaun D; de Mareuil J; Krchnak V; MacGregor RR;
       Chermann JC; Hirsch I; INSERM U322, Unite de Recherches sur les
       Retrovirus et; Maladies, Associees, Marseille, France.
 SO    Vaccine. 1995 Feb;13(3):321-5. Unique Identifier : AIDSLINE MED/95358028
 AB    The prototype virus HIV-1 LAV and highly cytopathic Zairian virus HIV-1
       NDK belong to the genetic subtypes B and D and represent low and highly
       cytopathic phenotypes, respectively. Their neutralization pattern and
       serotype were studied with respect to differences in their genotypes and
       phenotypes. Sera from HIV-1-infected persons living in four
       geographically distant areas, Philadelphia (USA), Ribeirao Preto
       (Brazil), Marseille (France) and Kinshasa (Zaire), were tested for the
       presence of type-specific and group-specific cross-reacting neutralizing
       antibodies against HIV-1 LAV and HIV-1 NDK in a continuous cell line
       MT4. The majority of type-specific antibodies were directed against
       HIV-1 LAV in Philadelphia, Ribeirao Preto and Marseille, and against
       HIV-1 NDK in Kinshasa. However, some sera with an HIV-1 NDK
       type-specific neutralization pattern were also found in Philadelphia,
       Ribeirao Preto and Marseille. These results indicate that strains with
       an HIV-1 NDK-like serotype could be found outside Africa. The presence
       of type-specific neutralizing antibodies against HIV-1 NDK in sera from
       North and South America and Europe should be taken into account during
       attempts to serotype HIV as well as in the course of selection of HIV-1
       candidate strains for an AIDS vaccine.
 DE    Amino Acid Sequence  Antibody Specificity  Brazil/EPIDEMIOLOGY
       France/EPIDEMIOLOGY  Human  HIV Antibodies/*BLOOD  HIV
       Infections/*EPIDEMIOLOGY/*IMMUNOLOGY  HIV
       Seropositivity/EPIDEMIOLOGY/IMMUNOLOGY
       HIV-1/*CLASSIFICATION/*IMMUNOLOGY/PATHOGENICITY  Incidence  Molecular
       Sequence Data  Neutralization Tests  Prevalence  Support, Non-U.S. Gov't
       United States/EPIDEMIOLOGY  Zaire/EPIDEMIOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).